Added to YB: 2025-05-15
Pitch date: 2025-05-12
KRON [bullish]
Kronos Bio, Inc.
+22.22%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States.
Market Cap
$45.1M
Pitch Price
$0.72
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.98
P/E
-0.69
EV/Sales
-3.32
Sector
Biotechnology
Category
special_situation
Kronos Bio: Tang Buyout w/ Curious CVR Consideration
KRON: Tang buying Kronos ($45M mkt cap) for $0.57/sh + CVR after istisociclib cancellation. Key CVR: 100% of pre-closing net cash >$40M threshold (vs $73.5M NCAV). Curious gap between threshold/NCAV raises red flags. Other CVR components include IP dispositions & lease-cost savings through 2028, but terms favor Tang with potential gaming.
Read full article (4 min)